HBM Healthcare Investments AG primarily focuses on direct investments and fund-of-funds strategies, with a particular emphasis on venture capital funds. The firm's direct investments cover a broad range of company maturity levels, from seed and early-stage startups to mid-stage and late-stage private enterprises, as well as emerging, small-cap public companies. Its investment scope also includes growth capital, management buyouts, and private investments in public equities (PIPEs). HBM actively seeks to finance spin-offs from larger corporations, support the expansion or restructuring of established businesses, and participate in all stages of venture capital funding. The fund is dedicated to the healthcare sector, investing in both private and public entities. Its focus areas within healthcare include human medicine, pharmaceuticals (drugs, biopharma), biotechnology, diagnostics, medical technology, and related industries. Initial investments are typically made in companies whose core products are in clinical development or the immediate pre-clinical phase. While HBM invests globally, it places a strategic emphasis on Asia Pacific, North America, and Europe. For public company investments, the preference is given to those that originated within its private portfolio. The fund often provides follow-on financing to its portfolio companies, including participation after an IPO. HBM primarily makes equity investments, but also utilizes other instruments like convertible bonds, debt securities, structured products, and derivatives. The firm may acquire majority stakes and typically secures a seat on the Board of Directors of its portfolio companies. Exits from these investments are generally achieved through a trade sale or an initial public offering.